Andrew Scharenberg, M.D.

Dr. Scharenberg is the founder and CEO of Umoja Biopharma. Umoja is pioneering a viral vector technology to deliver genes directly to a patient’s immune cells to engineer them to fight cancer. Before Umoja, Andy co-directed the Program in Cell & Gene Therapy at Seattle Children’s Research Institute. From 2000 to 2020, he was an attending Physician at Seattle Children’s Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School of Medicine. He earned his MD from the University of North Carolina School of Medicine, completed residency at the UNC Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital.